Ovarian cancer (OC) is the most lethal tumor of the female reproductive system, mainly because most cases are diagnosed at an advanced stage and show high recurrence and resistance to therapy. Advances in microbiome research have shown that microbial communities are closely linked to cancer development, progression, and treatment response. Microbiota in the gut and reproductive tract influence ovarian cancer through several mechanisms, including regulation of systemic immunity, maintenance or induction of chronic inflammation, hormonal effects, and metabolic changes. Microbial imbalance can enhance oncogenic signaling, weaken immune surveillance, and alter estrogen metabolism, which together promote tumor growth and contribute to chemoresistance. Microbial metabolites such as short-chain fatty acids and indole derivatives act as bioactive regulators of the tumor microenvironment, while microbial components like lipopolysaccharides can activate inflammatory pathways that support tumor survival. This review summarizes current evidence on the diverse roles of the microbiome in ovarian cancer biology and explains key links between microbial alterations and tumor pathophysiology. It also examines how gut and reproductive tract microbiota shape treatment outcomes, particularly responses to chemotherapy and immune checkpoint inhibitors. Emerging microbiome-based strategies, including probiotic interventions, fecal microbiota transplantation (FMT), and modulation of microbial metabolites, are highlighted for their potential to improve patient prognosis. With the integration of multi-omics technologies, artificial intelligence, and systems biology, the microbiome may become an important tool for early detection, personalized treatment, and precision oncology in ovarian cancer.